Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy.

Rani A, Stebbing J, Giamas G, Murphy J.

Front Endocrinol (Lausanne). 2019 May 24;10:245. doi: 10.3389/fendo.2019.00245. eCollection 2019. Review.

2.

EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR?

Bresciani G, Ditsiou A, Cilibrasi C, Vella V, Rea F, Schiavon M, Cavallesco NG, Giamas G, Zatelli MC, Gagliano T.

Endocr Connect. 2019 Jun 1;8(6):680-690. doi: 10.1530/EC-19-0192.

3.

Correction: Phosphorylation of CK1δ: identification of Ser370 as the major phosphorylation site targeted by PKA in vitro and in vivo.

Giamas G, Hirner H, Shoshiashvili L, Grothey A, Gessert S, Kühl M, Henne-Bruns D, Vorgias CE, Knippschild U.

Biochem J. 2019 Apr 18;476(8):1221-1225. doi: 10.1042/BJ-2007-0091_COR. No abstract available.

PMID:
31000625
4.

Astrocytes, the rising stars of the glioblastoma microenvironment.

Brandao M, Simon T, Critchley G, Giamas G.

Glia. 2019 May;67(5):779-790. doi: 10.1002/glia.23520. Epub 2018 Sep 21. Review.

PMID:
30240060
5.

Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma.

Simon T, Pinioti S, Schellenberger P, Rajeeve V, Wendler F, Cutillas PR, King A, Stebbing J, Giamas G.

Mol Cancer. 2018 Aug 31;17(1):132. doi: 10.1186/s12943-018-0878-x.

6.

LMTK3 confers chemo-resistance in breast cancer.

Stebbing J, Shah K, Lit LC, Gagliano T, Ditsiou A, Wang T, Wendler F, Simon T, Szabó KS, O'Hanlon T, Dean M, Roslani AC, Cheah SH, Lee SC, Giamas G.

Oncogene. 2018 Jun;37(23):3113-3130. doi: 10.1038/s41388-018-0197-0. Epub 2018 Mar 15.

7.

Tumor-Stromal Cell Communication: Small Vesicles Signal Big Changes.

Wendler F, Stamp GW, Giamas G.

Trends Cancer. 2016 Jul;2(7):326-329. doi: 10.1016/j.trecan.2016.05.007. Epub 2016 Jun 11.

PMID:
28741534
8.

Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.

Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G, Landi S.

PLoS One. 2017 Jun 22;12(6):e0180317. doi: 10.1371/journal.pone.0180317. eCollection 2017.

9.

Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling.

Simon T, Gagliano T, Giamas G.

Trends Mol Med. 2017 Mar;23(3):282-292. doi: 10.1016/j.molmed.2017.01.002. Epub 2017 Feb 2. Review.

PMID:
28162910
10.

Strategies in functional proteomics: Unveiling the pathways to precision oncology.

Favicchio R, Thepaut C, Zhang H, Arends R, Stebbing J, Giamas G.

Cancer Lett. 2016 Nov 1;382(1):86-94. doi: 10.1016/j.canlet.2016.01.049. Epub 2016 Feb 2. Review.

PMID:
26850375
11.

Extracellular vesicles swarm the cancer microenvironment: from tumor-stroma communication to drug intervention.

Wendler F, Favicchio R, Simon T, Alifrangis C, Stebbing J, Giamas G.

Oncogene. 2017 Feb 16;36(7):877-884. doi: 10.1038/onc.2016.253. Epub 2016 Aug 22. Review.

PMID:
27546617
12.

Proteome-wide dataset supporting functional study of tyrosine kinases in breast cancer.

Angelopoulos N, Stebbing J, Xu Y, Giamas G, Zhang H.

Data Brief. 2016 Mar 14;7:740-6. doi: 10.1016/j.dib.2016.03.024. eCollection 2016 Jun.

13.

ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation.

Nunes J, Zhang H, Angelopoulos N, Chhetri J, Osipo C, Grothey A, Stebbing J, Giamas G.

Oncotarget. 2016 May 10;7(19):27599-612. doi: 10.18632/oncotarget.8504.

14.

LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5.

Jacob J, Favicchio R, Karimian N, Mehrabi M, Harding V, Castellano L, Stebbing J, Giamas G.

Cancer Lett. 2016 Mar 1;372(1):137-46. doi: 10.1016/j.canlet.2015.12.026. Epub 2015 Dec 29.

PMID:
26739063
15.

Targeting tumor-stroma crosstalk: the example of the NT157 inhibitor.

Rampias T, Favicchio R, Stebbing J, Giamas G.

Oncogene. 2016 May 19;35(20):2562-4. doi: 10.1038/onc.2015.392. Epub 2015 Oct 19.

PMID:
26477311
16.

The many-faced KSR1: a tumor suppressor in breast cancer.

Zhang H, Stebbing J, Giamas G.

Oncoscience. 2015 Aug 25;2(8):669-70. eCollection 2015. No abstract available.

17.

Reply: When does a human being die?

Schofield GM, Urch CE, Stebbing J, Giamas G.

QJM. 2016 Feb;109(2):146. doi: 10.1093/qjmed/hcv164. Epub 2015 Sep 25. No abstract available.

PMID:
26408572
18.

LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer.

Xu Y, Zhang H, Nguyen VT, Angelopoulos N, Nunes J, Reid A, Buluwela L, Magnani L, Stebbing J, Giamas G.

Cell Rep. 2015 Aug 4;12(5):837-49. doi: 10.1016/j.celrep.2015.06.073. Epub 2015 Jul 23.

19.

Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative Proteomics.

Stebbing J, Zhang H, Xu Y, Grothey A, Ajuh P, Angelopoulos N, Giamas G.

Mol Cell Proteomics. 2015 Sep;14(9):2479-92. doi: 10.1074/mcp.M115.048090. Epub 2015 Jun 18.

20.

Proteomic profile of KSR1-regulated signalling in response to genotoxic agents in breast cancer.

Zhang H, Angelopoulos N, Xu Y, Grothey A, Nunes J, Stebbing J, Giamas G.

Breast Cancer Res Treat. 2015 Jun;151(3):555-68. doi: 10.1007/s10549-015-3443-y. Epub 2015 May 29.

21.

When does a human being die?

Schofield GM, Urch CE, Stebbing J, Giamas G.

QJM. 2015 Aug;108(8):605-9. doi: 10.1093/qjmed/hcu239. Epub 2014 Nov 28. Review.

PMID:
25434055
22.

Broader implications of SILAC-based proteomics for dissecting signaling dynamics in cancer.

Zhang H, Xu Y, Papanastasopoulos P, Stebbing J, Giamas G.

Expert Rev Proteomics. 2014 Dec;11(6):713-31. doi: 10.1586/14789450.2014.971115. Epub 2014 Oct 27. Review.

PMID:
25345469
23.

Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer.

Benhaim L, Zhang W, Wakatsuki T, Yang D, Gerger A, Bohanes P, Paez D, Loupakis F, LaBonte MJ, Ning Y, El-Khoueiry R, Ladner R, Wilson P, Zhang H, Giamas G, Stebbing J, Lenz HJ.

Pharmacogenomics J. 2015 Jun;15(3):235-40. doi: 10.1038/tpj.2014.58. Epub 2014 Oct 7.

PMID:
25287073
24.

Targeting lemurs against cancer metastasis.

Xu Y, Zhang H, Giamas G.

Oncotarget. 2014 Jul 30;5(14):5192-3. No abstract available.

25.

The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin β₁.

Xu Y, Zhang H, Lit LC, Grothey A, Athanasiadou M, Kiritsi M, Lombardo Y, Frampton AE, Green AR, Ellis IO, Ali S, Lenz HJ, Thanou M, Stebbing J, Giamas G.

Sci Signal. 2014 Jun 17;7(330):ra58. doi: 10.1126/scisignal.2005170.

PMID:
24939894
26.

KSR1 regulates BRCA1 degradation and inhibits breast cancer growth.

Stebbing J, Zhang H, Xu Y, Lit LC, Green AR, Grothey A, Lombardo Y, Periyasamy M, Blighe K, Zhang W, Shaw JA, Ellis IO, Lenz HJ, Giamas G.

Oncogene. 2015 Apr 16;34(16):2103-14. doi: 10.1038/onc.2014.129. Epub 2014 Jun 9.

PMID:
24909178
27.

MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.

Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G, Landi S.

PLoS One. 2014 Jan 21;9(1):e85935. doi: 10.1371/journal.pone.0085935. eCollection 2014. Erratum in: PLoS One. 2017 Jun 22;12 (6):e0180317.

28.

SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1.

Zhang H, Xu Y, Filipovic A, Lit LC, Koo CY, Stebbing J, Giamas G.

Br J Cancer. 2013 Nov 12;109(10):2675-84. doi: 10.1038/bjc.2013.628. Epub 2013 Oct 15.

29.

Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States.

Wakatsuki T, LaBonte MJ, Bohanes PO, Zhang W, Yang D, Azuma M, Barzi A, Ning Y, Loupakis F, Saadat S, Volz N, Stintzing S, El-Khoueiry R, Koizumi W, Watanabe M, Shah M, Stebbing J, Giamas G, Lenz HJ.

Mol Cancer Ther. 2013 Oct;12(10):2261-72. doi: 10.1158/1535-7163.MCT-12-1134. Epub 2013 Aug 5.

30.

The dual function of KSR1: a pseudokinase and beyond.

Zhang H, Koo CY, Stebbing J, Giamas G.

Biochem Soc Trans. 2013 Aug;41(4):1078-82. doi: 10.1042/BST20130042. Review.

PMID:
23863182
31.

Cancer stem cells--therapeutic targeting or therapy?

Filipovic A, Stebbing J, Giamas G.

Lancet Oncol. 2013 Jun;14(7):579-80. doi: 10.1016/S1470-2045(13)70258-4. No abstract available.

PMID:
23725700
32.

The regulatory roles of phosphatases in cancer.

Stebbing J, Lit LC, Zhang H, Darrington RS, Melaiu O, Rudraraju B, Giamas G.

Oncogene. 2014 Feb 20;33(8):939-53. doi: 10.1038/onc.2013.80. Epub 2013 Mar 18. Review.

PMID:
23503460
33.

Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen.

Winder T, Giamas G, Wilson PM, Zhang W, Yang D, Bohanes P, Ning Y, Gerger A, Stebbing J, Lenz HJ.

Pharmacogenomics J. 2014 Feb;14(1):28-34. doi: 10.1038/tpj.2013.8. Epub 2013 Mar 5.

PMID:
23459444
34.

Claudin-1 as a promoter of EMT in hepatocellular carcinoma.

Stebbing J, Filipović A, Giamas G.

Oncogene. 2013 Oct 10;32(41):4871-2. doi: 10.1038/onc.2012.591. Epub 2013 Jan 14.

PMID:
23318416
35.

LATS2 is a modulator of estrogen receptor alpha.

Lit LC, Scott S, Zhang H, Stebbing J, Photiou A, Giamas G.

Anticancer Res. 2013 Jan;33(1):53-63.

PMID:
23267128
36.

Nicastrin regulates breast cancer stem cell properties and tumor growth in vitro and in vivo.

Lombardo Y, Filipović A, Molyneux G, Periyasamy M, Giamas G, Hu Y, Trivedi PS, Wang J, Yagüe E, Michel L, Coombes RC.

Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16558-63. doi: 10.1073/pnas.1206268109. Epub 2012 Sep 24.

37.

LMTK3 is implicated in endocrine resistance via multiple signaling pathways.

Stebbing J, Filipovic A, Lit LC, Blighe K, Grothey A, Xu Y, Miki Y, Chow LW, Coombes RC, Sasano H, Shaw JA, Giamas G.

Oncogene. 2013 Jul 11;32(28):3371-80. doi: 10.1038/onc.2012.343. Epub 2012 Aug 6.

PMID:
22869149
38.

MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors.

Jiao LR, Frampton AE, Jacob J, Pellegrino L, Krell J, Giamas G, Tsim N, Vlavianos P, Cohen P, Ahmad R, Keller A, Habib NA, Stebbing J, Castellano L.

PLoS One. 2012;7(2):e32068. doi: 10.1371/journal.pone.0032068. Epub 2012 Feb 22.

39.

The role of pseudokinases in cancer.

Zhang H, Photiou A, Grothey A, Stebbing J, Giamas G.

Cell Signal. 2012 Jun;24(6):1173-84. doi: 10.1016/j.cellsig.2012.01.017. Epub 2012 Feb 4. Review.

PMID:
22330072
40.

Lemur tyrosine kinase-3 (LMTK3) in cancer and evolution.

Stebbing J, Filipović A, Giamas G.

Oncotarget. 2011 Jun;2(6):428-9. No abstract available.

41.

LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome.

Stebbing J, Filipovic A, Ellis IO, Green AR, D'Silva TR, Lenz HJ, Coombes RC, Wang T, Lee SC, Giamas G.

Breast Cancer Res Treat. 2012 Apr;132(2):537-44. doi: 10.1007/s10549-011-1622-z. Epub 2011 Jun 14.

PMID:
21671015
42.

Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer.

Giamas G, Filipović A, Jacob J, Messier W, Zhang H, Yang D, Zhang W, Shifa BA, Photiou A, Tralau-Stewart C, Castellano L, Green AR, Coombes RC, Ellis IO, Ali S, Lenz HJ, Stebbing J.

Nat Med. 2011 Jun;17(6):715-9. doi: 10.1038/nm.2351. Epub 2011 May 22.

PMID:
21602804
43.

The potential role of cyclooxygenase-2 (COX-2) during early breast cancer therapy.

Filipovic A, Giamas G, Stebbing J.

Ann Oncol. 2011 Aug;22(8):1700-2. doi: 10.1093/annonc/mdr266. Epub 2011 May 6. No abstract available.

PMID:
21551001
44.

Kinases as targets in the treatment of solid tumors.

Giamas G, Man YL, Hirner H, Bischof J, Kramer K, Khan K, Ahmed SS, Stebbing J, Knippschild U.

Cell Signal. 2010 Jul;22(7):984-1002. doi: 10.1016/j.cellsig.2010.01.011. Epub 2010 Jan 21. Review.

PMID:
20096351
45.

The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response.

Castellano L, Giamas G, Jacob J, Coombes RC, Lucchesi W, Thiruchelvam P, Barton G, Jiao LR, Wait R, Waxman J, Hannon GJ, Stebbing J.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15732-7. doi: 10.1073/pnas.0906947106. Epub 2009 Aug 24.

46.

CK1delta modulates the transcriptional activity of ERalpha via AIB1 in an estrogen-dependent manner and regulates ERalpha-AIB1 interactions.

Giamas G, Castellano L, Feng Q, Knippschild U, Jacob J, Thomas RS, Coombes RC, Smith CL, Jiao LR, Stebbing J.

Nucleic Acids Res. 2009 May;37(9):3110-23. doi: 10.1093/nar/gkp136. Epub 2009 Apr 1.

47.

The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer.

Mintz PJ, Habib NA, Jones LJ, Giamas G, Lewis JS, Bowen RL, Coombes RC, Stebbing J.

Cancer. 2008 Sep 15;113(6):1489-95. doi: 10.1002/cncr.23699.

48.

Bendamustine as a model for the activity of alkylating agents.

Apostolopoulos C, Castellano L, Stebbing J, Giamas G.

Future Oncol. 2008 Jun;4(3):323-32. doi: 10.2217/14796694.4.3.323. Review.

PMID:
18518757
49.

Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo.

Brockschmidt C, Hirner H, Huber N, Eismann T, Hillenbrand A, Giamas G, Radunsky B, Ammerpohl O, Bohm B, Henne-Bruns D, Kalthoff H, Leithäuser F, Trauzold A, Knippschild U.

Gut. 2008 Jun;57(6):799-806. doi: 10.1136/gut.2007.123695. Epub 2008 Jan 18.

PMID:
18203806
50.

Phosphorylation at Ser244 by CK1 determines nuclear localization and substrate targeting of PKD2.

von Blume J, Knippschild U, Dequiedt F, Giamas G, Beck A, Auer A, Van Lint J, Adler G, Seufferlein T.

EMBO J. 2007 Nov 14;26(22):4619-33. Epub 2007 Oct 25.

Supplemental Content

Loading ...
Support Center